Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
June 21, 2022 08:00 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the...
Celldex Announces Two New Appointments to its Board of Directors
June 16, 2022 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Cheryl L. Cohen and Dr. Garry Neil to the company’s Board of...
Celldex to Present at the 2022 Jefferies Global Healthcare Conference
June 06, 2022 16:05 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global...
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022
May 19, 2022 09:23 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with...
Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. ...
Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 28, 2022 16:01 ET
|
Celldex Therapeutics, Inc.
CSU Phase 1b multi-dose data expected in JulyCDX-0159 subcutaneous formulation study results fully support transition to SubQ dosing; Phase 2 studies in CSU and CIndU to initiate Q2 2022Expanded...
Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call
February 22, 2022 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to...
Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 16:05 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB...
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis
December 08, 2021 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of...
Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021
November 12, 2021 07:00 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual...